User profiles for Andreas M. Schmitt
Andreas Michael SchmittDepartment of Medical Oncology, University Hospital Basel, Basel, Switzerland Verified email at usb.ch Cited by 1365 |
[HTML][HTML] Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs)
on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …
on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …
[HTML][HTML] Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring
(CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in …
(CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in …
[HTML][HTML] Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis
Importance Convalescent plasma is a proposed treatment for COVID-19. Objective To assess
clinical outcomes with convalescent plasma treatment vs placebo or standard of care in …
clinical outcomes with convalescent plasma treatment vs placebo or standard of care in …
[HTML][HTML] Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer
Patients with cancer are at greater risk of severe COVID-19 and have been prioritised for
COVID-19 vaccination globally. We previously showed that following two doses of COVID-19 …
COVID-19 vaccination globally. We previously showed that following two doses of COVID-19 …
[PDF][PDF] Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer
Patients with cancer are at higher risk of severe COVID-19 (Grivas et al., 2021; Kuderer et al.,
2020), and they are currently prioritized globally for a third COVID-19 vaccine dose. …
2020), and they are currently prioritized globally for a third COVID-19 vaccine dose. …
Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways
…, R Wardenaar, DCJ Spierings, C Spencer, AM Schmitt… - Cancer discovery, 2023 - AACR
Despite treatment advances, melanoma remains a deadly disease at stage IV. Through research
autopsy and dense sampling of metastases combined with extensive multiomic profiling…
autopsy and dense sampling of metastases combined with extensive multiomic profiling…
[HTML][HTML] Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical …
Background Convalescent plasma has been widely used to treat COVID-19 and is under
investigation in numerous randomized clinical trials, but results are publicly available only for a …
investigation in numerous randomized clinical trials, but results are publicly available only for a …
[HTML][HTML] Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the
prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. …
prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. …
Clinical trial evidence supporting US food and drug administration approval of novel cancer therapies between 2000 and 2016
Importance Clinical trial evidence used to support drug approval is typically the only information
on benefits and harms that patients and clinicians can use for decision-making when …
on benefits and harms that patients and clinicians can use for decision-making when …
[PDF][PDF] Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer
Patients with blood cancer continue to have a greater risk of inadequate immune responses
following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the …
following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the …